<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051930</url>
  </required_header>
  <id_info>
    <org_study_id>TQC3721-I-01</org_study_id>
    <nct_id>NCT05051930</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of TQC3721 Suspension for Inhalation</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of TQC3721 Suspension for Inhalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721&#xD;
      suspension for inhalation in single/multiple administration(s) in healthy subjects; to&#xD;
      evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple&#xD;
      administrations in patients with Chronic Obstructive Pulmonary Disease（COPD）and asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From the enrollment of the subjects to 72 hours after the last administration</time_frame>
    <description>The Number of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From the enrollment of the subjects to 72 hours after the last administration</time_frame>
    <description>The Incidence of adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events related to the study drug</measure>
    <time_frame>From the enrollment of the subjects to 72 hours after the last administration</time_frame>
    <description>The number of adverse events associated with the study drug assessed by CTCAE V5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events associated with the study drug</measure>
    <time_frame>From the enrollment of the subjects to 72 hours after the last administration</time_frame>
    <description>Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Curve（AUC）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma drug peak concentration（Cmax ）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Plasma drug peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak（Tmax）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Time to maximum concentration following drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life time（t1/2）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Apparent terminal elimination half-life following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution（Vd）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance（CL）</measure>
    <time_frame>Within 60 minutes before each administration, to 72 hours after administration</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in the first second (FEV1) for patients with Chronic Obstructive Pulmonary Disease（COPD） or asthma</measure>
    <time_frame>From before administration to 3 hours after administration</time_frame>
    <description>Mean Change From Baseline in Peak FEV1 (Over 3 Hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline FEV1 to Morning Trough FEV1</measure>
    <time_frame>From the enrollment of the subjects to to 72 hours after administration</time_frame>
    <description>Mean Change From Baseline FEV1 to Morning Trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline FEV1 to Average FEV1</measure>
    <time_frame>From the enrollment of the subjects to to 72 hours after administration</time_frame>
    <description>Mean Change From Baseline FEV1 to Average FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test (CAT) for patients with COPD</measure>
    <time_frame>From enrollment to 4 weeks after administration</time_frame>
    <description>Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week 4.The score range is 0 to 40 (0 to 10 is minor influence;11 to 20 is moderate; 21 to30 is severe;31 to 40 is very severe), and more than 10 indicates more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified medical research council(mMRC) for patients with COPD or asthma</measure>
    <time_frame>From enrollment to 4 weeks after administration</time_frame>
    <description>Mean Change From Baseline in mMRC Scoring at Week 4.The severity is measured on a five-point scale from 0 to 4, with a higher score indicating more severe respiratory distress.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>TQC3721 suspension for inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQC3721 suspension placebo for inhalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQC3721 suspension for inhalation</intervention_name>
    <description>Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.</description>
    <arm_group_label>TQC3721 suspension for inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQC3721 suspension placebo for inhalation</intervention_name>
    <description>Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .</description>
    <arm_group_label>TQC3721 suspension placebo for inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent form before the trial, fully understand the content, process&#xD;
             and possible adverse reactions of the test;&#xD;
&#xD;
          -  Able to complete the study according to the requirements of protocol;&#xD;
&#xD;
          -  Aged between 18 and 65 years old, both men and women;&#xD;
&#xD;
          -  For healthy subjects: Male ≥50kg, female ≥45kg,body mass index(BMI)=weight (kg)/height&#xD;
             2 (m2), BMI is 18-28 kg/m2 (including the critical value); For patients: BMI is 18-28&#xD;
             kg/m2 (including the critical value), and body weight is ≥45kg.&#xD;
&#xD;
          -  For healthy subjects: normal or abnormal vital signs, physical examination, laboratory&#xD;
             examination, electrocardiogram, and imageological examination have no clinical&#xD;
             significance;&#xD;
&#xD;
          -  For healthy subjects: FEV1 and forced vital capacity(FVC) are at least 90% of the&#xD;
             predicted values;&#xD;
&#xD;
          -  Subjects (including male subjects) have no pregnancy plan and have voluntarily taken&#xD;
             effective contraceptive measures for at least 1 month after being screened to the last&#xD;
             use of the study drug;&#xD;
&#xD;
          -  For patients: Vital signs range: systolic blood pressure 90 to 140mmHg, diastolic&#xD;
             blood pressure 50 to 90 mmHg, heart rate 50 to 90 bpm;&#xD;
&#xD;
          -  For patients: 12-lead electrocardiogram with QT interval corrected ≤450 msec (males)&#xD;
             or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no&#xD;
             morphologic and other clinical significant abnormalities (such as left band branch&#xD;
             block, atrioventricular node dysfunction, ischemic ST segment abnormalities);&#xD;
&#xD;
          -  For patients: Ability to perform acceptable and reproducible spirometry;&#xD;
&#xD;
          -  For patients: According to the diagnostic criteria of 2018 Practical Edition of&#xD;
             Guidelines for the Diagnosis and Treatment of COPD, the patient was diagnosed with&#xD;
             COPD for at least 1 year;Post-bronchodilator spirometry at screening must demonstrate&#xD;
             FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal;&#xD;
&#xD;
          -  For patients: mMRC Scoring at screening ≥2;&#xD;
&#xD;
          -  For patients: Clinically stable COPD in the previous 4 weeks;&#xD;
&#xD;
          -  For patients: Capable of withdrawing long acting bronchodilators until the end of the&#xD;
             treatment period, and short acting bronchodilators for 8 hours prior to administration&#xD;
             of study medication;&#xD;
&#xD;
          -  For patients: Current and former smokers with a smoking history of ≥10 pack&#xD;
             years（smoking at least 20 cigarettes a day for 10 years or at least 10 cigarettes a&#xD;
             day for 20 years）;&#xD;
&#xD;
          -  For patients: beta agonists are currently used only &quot;when needed&quot;;&#xD;
&#xD;
          -  For patients: Never smoked or An ex-smoker for ≥6 months；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preexisting or existing the neuropsychiatric system, respiratory system,&#xD;
             cardiovascular system, digestive system, hemo-lymphatic system, immune system, liver&#xD;
             and kidney dysfunction, endocrine system, musculoskeletal system, or other disease&#xD;
             that the investigator assesses that may affect drug metabolism or safety.&#xD;
&#xD;
          -  For healthy subjects: Have a history of fainting needles, fainting blood.&#xD;
&#xD;
          -  For healthy subjects: Known allergy to the study drug and their metabolites or any of&#xD;
             the excipients of the formulation.&#xD;
&#xD;
          -  For healthy subjects: Those who smoked more than 5 cigarettes per day during the 3&#xD;
             months before the trial.&#xD;
&#xD;
          -  A history of alcohol abuse in the past 6 months (14 units of alcohol consumed per&#xD;
             week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).&#xD;
&#xD;
          -  For healthy subjects: Donated blood or had substantial loss of blood (more than 400&#xD;
             mL) within 2 months before the test.&#xD;
&#xD;
          -  For healthy subjects: Had taken any prescription, over-the-counter, vitamin product or&#xD;
             herbal medicine within 1 month prior to the use of the study drug.&#xD;
&#xD;
          -  Participated in other clinical trials within 3 months prior to this study.&#xD;
&#xD;
          -  Positive for hepatitis (including hepatitis B and C), human immunodeficiency&#xD;
             virus（HIV） or syphilis at screening.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Positive test for alcohol.&#xD;
&#xD;
          -  For healthy subjects: Blood collection is difficult or cannot tolerate venipuncture&#xD;
             blood collection.&#xD;
&#xD;
          -  For healthy subjects: The subject is unable or can not comply with ward management&#xD;
             regulations.&#xD;
&#xD;
          -  For healthy subjects: The subject is unable to complete the study due to personal&#xD;
             reasons.&#xD;
&#xD;
          -  For healthy subjects: Any circumstances that the investigator considers to pose a&#xD;
             safety risk to the subject during the study or may interfere with the conduct of the&#xD;
             study.&#xD;
&#xD;
          -  For patients: Intolerance to salbutamol, tiotropium, or this product or prior exposure&#xD;
             to Ensifentrine (RPL554).&#xD;
&#xD;
          -  For patients: Use of any medicine within 4 weeks prior to initiation of the study&#xD;
             drug, including non-prescription medications and herbs, except vitamins.&#xD;
&#xD;
          -  For patients: Physical examination findings that researchers consider clinically&#xD;
             significant at the time of screening.&#xD;
&#xD;
          -  For patients: A history of cardiovascular disease (including arrhythmias) or active&#xD;
             hyperthyroidism.&#xD;
&#xD;
          -  For patients: History of malignancy of any organ system, treated or untreated within&#xD;
             the past 5 years, with the exception of localised basal cell carcinoma of the skin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weimin Li, Post Doctor</last_name>
    <phone>028-85423837</phone>
    <email>llllllv2@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin Li, Post Doctor</last_name>
      <phone>028-85423837</phone>
      <email>llllllv2@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

